The potency of aloe emodin-loaded nanoparticles in conjunction with IFN-γ for the pretreatment of mesenchymal stem cells with class II transactivator silence to alleviate severe acute pancreatitis

Abstract

Mesenchymal stem cells (MSCs) have a moderate impact on the therapy of severe acute pancreatitis. This study seeks to improve the therapeutic effectiveness of MSCs. By preconditioning them via the upregulation of critical anti-inflammatory molecules, so diminishing immune rejection, we are creating a path for more effective treatments. Aloe emodin (AE), a natural active monomer with low-toxicity, in conjunction with interferon gamma (IFN-γ) (I-AE), markedly upregulated immunosuppressive molecules indoleamine 2,3-dioxygenase and programmed cell death-Ligand 1 in MSCs, thereby pharmacologically modulating the inhibition of CD4 – T cell activation in vitro effectively. Transient transfection of small interfering RNA silenced the class II transactivator (CIITA) gene expression of umbilical cord mesenchymal stem cells (UMSCs) interfering with human leukocyte antigen class II expression to avert immune rejection. AE-loaded nanoparticles efficiently maintained proliferation inhibition of MSCs within a manageable range by sustained release. UMSCs pretreated by I-AE with CIITA silencing preserved pancreatic structure as evidenced by diminished acinar cell death, reduced pancreatic edema and inflammation, and significantly lowered serum amylase levels The encouraging potential of UMSCs with CIITA gene silencing combined with AE and IFN-γ pretreatment offers optimism for clinical application in pancreatitis therapy.

Keywords

aloe emodin/IFN-γ combination / histocompatibility complex II expression / mesenchymal stem cells / nanoparticles / severe acute pancreatitis

References

[1] ZeremE. Treatment of severe acute pancreatitis and its complications. World J Gastroenterol. 2014;20(38):13879-13892.

[2] BoxhoornL, Voermans RP, BouwenseSA, et al. Acute pancreatitis. Lancet. 2020;396(10252):726-734.

[3] BuxbaumJL, Quezada M, DaB, et al. Early aggressive hydration hastens clinical improvement in mild acute pancreatitis. Am J Gastroenterol. 2017;112(5):797-803.

[4] YaoH, HeC, DengL, Liao G. Enteral versus parenteral nutrition in critically ill patients with severe pancreatitis: a meta-analysis. Eur J Clin Nutr. 2018;72(1):66-68.

[5] WartmannT, Mayerle J, KähneT, et al. Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice. Gastroenterology. 2010;138(2):726-737.

[6] SadowskiSM. Epidural anesthesia improves pancreatic perfusion and decreases the severity of acute pancreatitis. World J Gastroenterol. 2015;21(43):12448-12456.

[7] TanZH, YuLH, WeiHL, Liu GT. Scutellarin protects against lipopolysaccharide-induced acute lung injury via inhibition of NF-κB activation in mice. J Asian Nat Prod Res. 2010;12(3):175-184.

[8] HanqingC, XipingZ, JingminO, Jun J, DijiongW. Research on scutellarin parenteral solution’s protective effects in rats with severe acute pancreatitis and multiple organ injuries. Inflammation. 2012;35(3):1005-1014.

[9] ShiY, WangY, LiQ, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14(8):493-507.

[10] FontaineMJ, ShihH, SchäferR, PittengerMF. Unraveling the mesenchymal stromal cells’ paracrine immunomodulatory effects. Transfus Med Rev. 2016;30(1):37-43.

[11] JiangW, XuJ. Immune modulation by mesenchymal stem cells. Cell Proliferation. 2020;53(1):e12712.

[12] AndrzejewskaA, Dabrowska S, LukomskaB, JanowskiM. Mesenchymal stem cells for neurological disorders. Adv Sci. 2021;8(7):2002944.

[13] Barrère-LemaireS, VincentA, Jorgensen C, PiotC, NargeotJ, DjouadF. Mesenchymal stromal cells for improvement of cardiac function following acute myocardial infarction: a matter of timing. Physiol Rev. 2024;104(2):659-725.

[14] SarmahD, DattaA, KaurH, et al. Sirtuin-1-mediated NF-κB pathway modulation to mitigate inflammasome signaling and cellular apoptosis is one of the neuroprotective effects of intra-arterial mesenchymal stem cell therapy following ischemic stroke. Stem Cell Rev Rep. 2022;18(2):821-838.

[15] ZhaoY, YangX, LiS, et al. sTNFRII-Fc modification protects human UC-MSCs against apoptosis/autophagy induced by TNF-α and enhances their efficacy in alleviating inflammatory arthritis. Stem Cell Res Ther. 2021;12(1):535.

[16] VigoT, Procaccini C, FerraraG, et al. IFN-γ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways. J Allergy Clin Immunol. 2017;139(5):1667-1676.

[17] LiuD, SongG, MaZ, et al. Resveratrol improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells in rats with severe acute pancreatitis. Int Immunopharmacol. 2020;80:106128.

[18] SilvaLHA, Antunes MA, Dos SantosCC, WeissDJ, CruzFF, RoccoPRM. Strategies to improve the therapeutic effects of mesenchymal stromal cells in respiratory diseases. Stem Cell Res Ther. 2018;9(1):45.

[19] HeX, YangY, YaoM, et al. Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79(10):1298-1304.

[20] LiuXB, JiangJM, HuangZW, et al. Clinical study on the treatment of severe acute pancreatitis by integrated traditional Chinese medicine and Western medicine. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004;35(2):204-208.

[21] WenY, HanC, LiuT, et al. Chaiqin chengqi decoction alleviates severity of acute pancreatitis via inhibition of TLR4 and NLRP3 inflammasome: identification of bioactive ingredients via pharmacological sub-network analysis and experimental validation. Phytomedicine. 2020;79:153328.

[22] SuJ, ChenX, HuangY, et al. Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ. 2014;21(3):388-396.

[23] DaviesLC, Heldring N, KadriN, Le BlancK. Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression. Stem Cells. 2017;35(3):766-776.

[24] MeiselR, ZibertA, LaryeaM, Göbel U, DäubenerW, DillooD. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103(12):4619-4621.

[25] FallarinoF, Grohmann U, PuccettiP. Indoleamine 2, 3-dioxygenase: from catalyst to signaling function. Eur J Immunol. 2012;42(8):1932-1937.

[26] DongH, StromeSE, SalomaoDR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800.

[27] LiM, SoderR, AbhyankarS, et al. WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1. J Extracell Vesicles. 2021;10(4):e12067.

[28] GianchecchiE, Delfino DV, FierabracciA. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev. 2013;12(11):1091-1100.

[29] ZhengW, WangC, DingR, Huang Y, LiY, LuY. Triptolide-loaded nanoparticles targeting breast cancer in vivo with reduced toxicity. Int J Pharm. 2019;572:118721.

[30] HuangY, XieP, YangST, et al. Carbon nanoparticles suspension injection for the delivery of doxorubicin: comparable efficacy and reduced toxicity. Mater Sci Eng C. 2018;92:416-423.

[31] RodríguezT, Méndez R, Del CampoA, et al. Patterns of constitutive and IFN-γ inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics. 2007;59(2):123-133.

[32] van den ElsenPJ, van der Stoep N, YazawaT. Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not? Am J Pathol. 2003;163(1):373-376. Author reply 375-376.

[33] OdebergJ, Plachter B, BrandénL, Söderberg-NauclérC. Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR α-chain. Blood. 2003;101(12):4870-4877.

[34] Stumptner-CuveletteP, Morchoisne S, DugastM, et al. HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proc Natl Acad Sci. 2001;98(21):12144-12149.

[35] ReithW, LeibundGut-Landmann S, WaldburgerJM. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol. 2005;5(10):793-806.

[36] ReithW, MachB. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol. 2001;19:331-373.

[37] DeSandroA, Nagarajan UM, BossJM. The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes. Am J Hum Genet. 1999;65(2):279-286.

[38] ChangCH, Guerder S, HongSC, van EwijkW, Flavell RA. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity. 1996;4(2):167-178.

[39] ChenH, LiY, LinX, et al. Functional disruption of human leukocyte antigen II in human embryonic stem cell. Biol Res. 2015;48:59.

[40] ColungaA, HirataR, RussellD. Generation of HLA class II deficient human embryonic stem cells by AAV mediated knockout of RFXANK. Mol Ther. 2014;22:S14.

[41] MunnDH, Shafizadeh E, AttwoodJT, BondarevI, Pashine A, MellorAL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189(9):1363-1372.

[42] BöttcherM, Hofmann AD, BrunsH, et al. Mesenchymal stromal cells disrupt mTOR-signaling and aerobic glycolysis during T-cell activation. Stem Cells. 2016;34(2):516-521.

[43] AugelloA, TassoR, NegriniSM, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol. 2005;35(5):1482-1490.

[44] PlataniasLC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375-386.

[45] LiS, YangK, CaoW, et al. Tanshinone IIA enhances the therapeutic efficacy of mesenchymal stem cells derived exosomes in myocardial ischemia/reperfusion injury via up-regulating miR-223-5p. J Control Release. 2023;358:13-26.

[46] LinCW, WuCF, HsiaoNW, et al. Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. Int J Antimicrob Agents. 2008;32(4):355-359.

[47] WanL, WangZ, ZhouL. Protecting effects of emodin on multiorgan failure of rats with severe acute pancreatitis. Pancreas. 2009;38(7):835-836.

[48] XiaXM, WangFY, WangZK, Wan HJ, XuWA, LuH. Emodin enhances alveolar epithelial barrier function in rats with experimental acute pancreatitis. World J Gastroenterol. 2010;16(24):2994-3001.

[49] LiZ, XiaX, ZhangS, Zhang A, BoW, ZhouR. Up-regulation of toll-like receptor 4 was suppressed by emodin and baicalin in the setting of acute pancreatitis. Biomed Pharmacother = Biomed Pharmacother. 2009;63(2):120-128.

[50] CaoYJ, PuZJ, TangYP, et al. Advances in bio-active constituents, pharmacology and clinical applications of rhubarb. Chin Med. 2017;12:36.

[51] KusskeAM, Rongione AJ, AshleySW, McFaddenDW, ReberHA. Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice. Surgery. 1996;120(2):284-289. Discussion 289.

[52] OsmanMO, Kristensen JU, JacobsenNO, et al. A monoclonal anti-interleukin 8 antibody (WS-4) inhibits cytokine response and acute lung injury in experimental severe acute necrotising pancreatitis in rabbits. Gut. 1998;43(2):232-239.

RIGHTS & PERMISSIONS

2024 2024 The Author(s). MedComm - Biomaterials and Applications published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).